Nisa Investment Advisors’s Coherus Oncology CHRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $970 | Hold |
574
| – | – | ﹤0.01% | 2753 |
|
|
2025
Q4 | $815 | Hold |
574
| – | – | ﹤0.01% | 2743 |
|
|
2025
Q3 | $941 | Sell |
574
-25
| -4% | -$28 | ﹤0.01% | 2755 |
|
|
2025
Q2 | $438 | Sell |
599
-4,086
| -87% | -$3.53K | ﹤0.01% | 2893 |
|
|
2025
Q1 | $3.78K | Buy |
4,685
+8
| +0.2% | +$9 | ﹤0.01% | 2316 |
|
|
2024
Q4 | $6.45K | Buy |
4,677
+663
| +17% | +$744 | ﹤0.01% | 2226 |
|
|
2024
Q3 | $4.17K | Sell |
4,014
-16,643
| -81% | -$22.8K | ﹤0.01% | 2251 |
|
|
2024
Q2 | $35.7K | Buy |
20,657
+19,912
| +2,673% | +$40.1K | ﹤0.01% | 1766 |
|
|
2024
Q1 | $1.78K | Buy |
745
+135
| +22% | +$332 | ﹤0.01% | 2255 |
|
|
2023
Q4 | $2.03K | Sell |
610
-105
| -15% | -$281 | ﹤0.01% | 2183 |
|
|
2023
Q3 | $2.67K | Buy |
715
+55
| +8% | +$254 | ﹤0.01% | 2331 |
|
|
2023
Q2 | $2.82K | Buy |
660
+25
| +4% | +$148 | ﹤0.01% | 2351 |
|
|
2023
Q1 | $4K | Buy |
635
+25
| +4% | +$194 | ﹤0.01% | 2255 |
|
|
2022
Q4 | $5K | Sell |
610
-70
| -10% | -$539 | ﹤0.01% | 2294 |
|
|
2022
Q3 | $6K | Buy |
680
+70
| +11% | +$708 | ﹤0.01% | 2264 |
|
|
2022
Q2 | $4K | Sell |
610
-27,470
| -98% | -$239K | ﹤0.01% | 2290 |
|
|
2022
Q1 | $363K | Sell |
28,080
-250
| -0.9% | -$3.18K | ﹤0.01% | 1176 |
|
|
2021
Q4 | $350K | Sell |
28,330
-1,830
| -6% | -$32K | ﹤0.01% | 1110 |
|
|
2021
Q3 | $485 | Hold |
30,160
| – | – | ﹤0.01% | 1129 |
|
|
2021
Q2 | $417 | Buy |
30,160
+2,100
| +7% | +$29.7K | ﹤0.01% | 1180 |
|
|
2021
Q1 | $410 | Hold |
28,060
| – | – | ﹤0.01% | 1223 |
|
|
2020
Q4 | $488K | Buy |
28,060
+850
| +3% | +$15.1K | ﹤0.01% | 1163 |
|
|
2020
Q3 | $499K | Buy |
27,210
+2,300
| +9% | +$42.8K | ﹤0.01% | 1049 |
|
|
2020
Q2 | $445K | Hold |
24,910
| – | – | ﹤0.01% | 1057 |
|
|
2020
Q1 | $404K | Buy |
24,910
+120
| +0.5% | +$2.22K | ﹤0.01% | 996 |
|
|
2019
Q4 | $446K | Hold |
24,790
| – | – | ﹤0.01% | 1129 |
|
|
2019
Q3 | $502K | Buy |
24,790
+180
| +0.7% | +$3.6K | ﹤0.01% | 1089 |
|
|
2019
Q2 | $544K | Hold |
24,610
| – | – | 0.01% | 1051 |
|
|
2019
Q1 | $336K | Hold |
24,610
| – | – | ﹤0.01% | 1171 |
|
|
2018
Q4 | $223K | Sell |
24,610
-4,000
| -14% | -$46.3K | ﹤0.01% | 1212 |
|
|
2018
Q3 | $472K | Buy |
28,610
+310
| +1% | +$5.5K | ﹤0.01% | 1114 |
|
|
2018
Q2 | $396K | Hold |
28,300
| – | – | ﹤0.01% | 1118 |
|
|
2018
Q1 | $313K | Hold |
28,300
| – | – | ﹤0.01% | 1137 |
|
|
2017
Q4 | $249K | Buy |
+28,300
| New | +$303K | ﹤0.01% | 1209 |
|
|
2017
Q2 | – | Sell |
-210
| Closed | -$4K | – | 1840 |
|
|
2017
Q1 | $4K | Sell |
210
-190
| -48% | -$4.67K | ﹤0.01% | 1820 |
|
|
2016
Q4 | $11K | Sell |
400
-200
| -33% | -$5.6K | ﹤0.01% | 1785 |
|
|
2016
Q3 | $16K | Buy |
+600
| New | +$16.4K | ﹤0.01% | 1714 |
|
Other funds holding CHRS
VCM
SB
KKRC
CM
CWG
Nisa Investment Advisors's CHRS Position: Q1 2026 in Review
Nisa Investment Advisors held its Coherus Oncology (CHRS) position steady in Q1 2026 at 574 shares worth $970. The position accounts for ﹤0.01% of the portfolio, ranked #2753.
Nisa Investment Advisors first reported a position in CHRS in Q3 2016 and has held it in 37 quarters since. The position peaked at $544K in Q2 2019. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.
- Nisa Investment Advisors held 574 shares of Coherus Oncology worth $970 as of Q1 2026.
- Nisa Investment Advisors left its Coherus Oncology share count unchanged in Q1 2026.
- Coherus Oncology made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #2753 holding.
- Nisa Investment Advisors first reported a position in Coherus Oncology in Q3 2016 and has held it in 37 quarters since.
- Nisa Investment Advisors's Coherus Oncology position peaked at $544K in Q2 2019.
- 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.
Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.